姓名：施文瑜
职称：教授，主任医师
个人简介：江苏南通人，医学博士。
专业研究领域：血液肿瘤、淋巴瘤。
专著与论集：
1） 郑维成，施文瑜＊。sod1抑制剂诱导dlbcl细胞凋亡。中国实验血液学杂志 2023
2）yao wang#, minan zhang#, qingfeng xue, huan zhou, jie chen, hong wang, yaping zhang*, wenyu shi*，case report: immune modulation after pd-1 inhibitor therapy in a patient with extranodal nk/t-cell lymphoma secondary to chronic active epstein-barr virus disease unveiled by single-cell transcriptomics frontiers in immunology 2023
通讯作者，sci收录（一区），影响因子：8
3）xiyue yan#, juan liu#, yu ben, weicheng zheng, pan hu, yaping zhang*, wenyu shi*，a rare b-myeloid conversion of follicular lymphoma into clonally related acute myeloid leukemia life (basel). 2023 mar 8;13(3):729
通讯作者，sci收录（三区），影响因子：3.2
4）chen w, ni d, zhang h, li x, jiang y, wu j, gu y, gao m, shi w, song j, wenyu shi*，over-expression of usp15/mmp3 predict poor prognosis and promote growth, migration in non-small cell lung cancer cells cancer genet. 2023 jan 7;272-273:9-15.
通讯作者，sci收录（四区），影响因子：2.1
5）jing he＃ , qingfeng xue＃，xin hua＃ , quanqing li，ziwei chen, cindy zhu and wenyu shi*，association between environmental phenols and all‐cause and cancer mortality environ sci pollut res int. 2023 mar;30(12):33432-37
通讯作者，sci收录（二区），影响因子：5
6） 刘娟，颜希月，张亚平，施文瑜＊。18f-fdg pet/ct 在黏膜相关淋巴组织淋巴瘤中的临床应用价值。中国临床研究 2022，5（35）649-54
7） shike li＃ , qingfeng xue＃ and wenyu shi*， primary osteosarcoma of the breast: a rare case report and literature review, frontiers in oncology, 2022;12:875793.
通讯作者，sci收录（二区），影响因子： 5
8） jing he＃ , ziwei chen＃ , qingfeng xue＃ , pingping sun , yuan wang , cindy zhu and wenyu shi*， identification of molecular subtypes and a novel prognostic model of diffuse large b-cell lymphoma based on a metabolism-associated gene signature journal of translational medicine, 2022;20:186.通讯作者，sci收录（一区），影响因子： 8
9） jing he＃ , ziwei chen＃ , qingfeng xue and wenyu shi*， block of proliferation promotes proliferation, invasion and epithelial mesenchymal transformation in gastric cancer oxidative medicine and cellular longevity, 2022 feb 16;2022:2946989.
通讯作者，sci收录（二区），影响因子： 5
10） yuan wang＃, jing he＃, manyu xu, qingfeng xue, cindy zhu, juan liu1, yaping zhang＊ and wenyu shi*， holistic view of alk tki resistance in alk-positive anaplastic large cell lymphoma. frontiers in oncology, 2022;12:815654.
通讯作者，sci收录（二区），影响因子： 5
11） ziwei chen＃, jing he＃and wenyu shi*， association between urinary environmental phenols and the prevalence of cardiovascular diseases in us adults environmental science and pollution research, 2022; jan 29.
通讯作者，sci收录（二区），影响因子： 4
12） weicheng zheng＃，qingfeng xue＃, xueping sha＃, yao wang, yuan wang, juan liu, yaping zhang＊, wenyu shi＊ successful pd-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to car-t cell therapy: a case report journal of cancer research and clinical oncology. cancer biology & therapy, 2021 dec 2;22(10-12):537-543.
通讯作者，sci收录（三区），影响因子： 3
13） wei wang＃, qianqian wu＃, ziheng wang＃, shiqi ren, hanyu shen, wenyu shi＊ and yunzhao xu*，development of a prognostic model for ovarian cancer patients based on novel immune microenvironment related genes. frontiers in oncology, 2021;11:647273.
共同通讯作者，sci收录（二区），影响因子： 6.2
14） pan hu＃，yuben＃，juan liu，weicheng zheng，xiyue yan，yaping zhang＊， wenyu shi＊ promising response to lenalidomide-combination therapy in a discordant lymphoma consisting of ebv-positive diffuse large b-cell lymphoma and angioimmunoblastic t-cell lymphoma: a case report oncotargets and therapy. 2021:14 2489–2495
通讯作者，sci收录（三区），影响因子： 4.08
15） yunzhao xu＃， wei wang＃，shuting gu， qinqin liu，jinling chen， haixia mao， yuanlin liu，qinghua xi＊，wenyu shi＊ high neuropilin and tolloid-like expression associated with metastasis and poor survival in epithelial ovarian cancer via regulation of actin cytoskeleton. j cell mol med 2020;24:9114–9124.
通讯作者，sci收录（二区），影响因子： 4.08
16） hong zhou＃, pan hu＃, xiyue yan, yaping zhang＊, and wenyu shi＊. ibrutinib in chronic lymphocytic leukemia: clinical applications, drug resistance, and prospects. oncotargets and therapy. 2020:13 4877–4892
通讯作者，sci收录（三区），影响因子： 3.08
17）hong zhou＃, li yang＃, qingxiu dang, jianfei huang, yuehua cheng, yaping zhang＊, and wenyu shi＊. ibrutinib resistance in a patient with transformed diffuse large b-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma. cancer biol ther. 2020 apr 2;21(4):303-308
通讯作者，sci收录（三区），影响因子： 3.29
18）bhawana george＃, suraj konnath george＃, wenyu shi＃, abedul haque, ping shi, ghazaleh eskandari, magnus axelson, olle larsson, ahmed o. kaseb, hesham m. amin＊. dual inhibition of igf-ir and alk as an effective strategy to eradicate npm-alk t-cell lymphoma. j hematol oncol. 2019 jul 24;12(1):80. 共同第一作者，sci收录（一区），影响因子： 11.3
19）qingxiu dang＃, lili chen＃, mengqi xu＃, xuefen you, hong zhou, yaping zhang＊, wenyu shi＊， the γ-secretase inhibitor gsi-i interacts synergistically with the proteasome t inhibitor bortezomib to induce alk anaplastic large cell lymphoma cell apoptosis. cellular signalling 2019 (59):76-84. 通讯作者，通讯作者，sci收录（二区），影响因子： 3.5
20）qingxiu dang＃, hong zhou＃, juan qian＃, li yang, jianfei huang, yaping zhang＊, wenyu shi＊. lamp1 overexpression predicts poor prognosis in diffuse large b cell lymphoma. clinical lymphoma, myeloma and leukemia 2018 nov;18(11):749 通讯作者，sci收录（三区），影响因子： 2.5
21）yaping zhang＃, xinfeng wang＃, yifei liu, chunfeng sun, wenyu shi＊, hongming huang＊. lenalidomide combined with r-gdp in a patient with refractory cd5-positive diffuse large b-cell lymphoma: a promising response and review. cancer biol ther. 2018 jul 3;19(7):549-553.
共同通讯作者，sci收录（三区），影响因子： 3.29
国际学术会议报告：
） wenyu shi，yuan wang, yaping zhang, haixia cao and guangcan gao. identification and verification of immune-related gene prognostic signature based on ssgsea for dlbcl在2023年欧洲血液学年会进行报告，摘要已被会议收录
2） wenyu shi， hong zhou， yaping zhang， jianfei huang， pan hu， jianyong li. gsk1838705a, an igf-1r/alk inhibitor, overcomes crizotinib resistance in alk alcl在2019年美国61届血液学年会进行报告，摘要已被blood收录
3） wenyu shi＃， qingxiu dang, hong zhou, juan qian, yaping zhang. lamp1 overexpression predicts poor prognosis in diffuse large b cell lymphoma 在2017年香港李嘉诚医学院郑裕彤奖学金学术报告会壁报交流
主要科研项目
主持多项省部级以上科研项目，其中包括国家自然科学基金项目2项。
讲授课程
肿瘤学进展
指导研究生情况
已毕业硕士生9名；在读博士生3名，硕士生13名。
